share_log
  • Headlines
  • Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects

Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects

Benzinga ·  Nov 14 21:20
Moleculin Amends Clinical Trial Protocol With FDA For Its Phase 3 Trial Of Annamycin In Combination With Cytarabine; Amended Protocol Accelerates Unblinding Of Prelim. Primary Efficacy Data And Safety/Tolerability Of Three Arms At First 45 Subjects
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated